Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses the results of the RxPONDER study, a Phase III trial evaluating whether the Oncotype DX® test can be used to spare chemotherapy in women with node-positive early-stage breast cancer. In this study, over 5000 women with an Oncotype DX Breast Recurrence Score ® were enrolled, in postmenopausal women with a recurrence score of 0-25, there was no benefit from chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

свернуть